A Study Of Retinal Function In Eyes Treated For Diabetic Macular Edema With Anti-VEGF Agents

Overview

About this study

The primary purpose of this study is to define the ocular structural and functional characteristics of eyes with DME requiring treatment and describe the changes in ocular structural and functional characteristics through 48 weeks after treatment initiation

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥18 years

  • Diagnosed with Type 1 or Type 2 diabetes

  • Best corrected visual acuity 20/320 or better (Snellen) (≥24 ETDRS letters)

  • At least 1 eye with CI-DME requiring treatment

  • Able and willing to provide informed consent

Exclusion Criteria:

  • Ocular or systemic condition, aside from diabetes mellitus (DM), that is likely to affect the assessment of DRSS, DME, or the functioning of the neural retina.

  • Previous treatment of any kind for diabetic retinopathy or DME

  • Any condition that may preclude adequate imaging of the macula (e.g. dense cataract or other media opacity, ptosis)

  • History of rhegmatogenous retinal detachment or macular hole History of vitrectomy

  • Intraocular surgery (including cataract surgery) within 4 months prior to enrollment or anticipated within the next 6 months

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 04/27/2026. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andrew Barkmeier, M.D.

Contact us for the latest status

Contact information:

Suzanne Wernimont

5075388119

wernimont.suzanne@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20604606

Mayo Clinic Footer